Physician profile
Robyn E Jimenez
NPI 1437163979
$1,876.63
in general payments reported to CMS, 2019-2025
20 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $470 · 2023: $297 · 2024: $503 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $382.22 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $252.06 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $203.25 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.85 | 2021-2024 | Tradjenta, Jardiance, Synjardy |
| Astellas Pharma US INC | $113.11 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $111.18 | 2021-2025 | Airsupra |
| Exact Sciences Corporation | $100.56 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $85.31 | 2022-2025 | |
| Abbott Laboratories | $84.40 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $78.12 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $62.59 | 2023-2025 | Rexulti |
| Pfizer INC. | $41.34 | 2023-2024 | |
| Dexcom, INC. | $37.60 | 2024-2025 | Dexcom G6 Transmitter |
| Silk Road Medical, INC. | $23.23 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Esperion Therapeutics, INC. | $23.08 | 2025 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $22.93 | 2025 | |
| Noven Therapeutics, LLC | $21.82 | 2024 | Xelstrym |
| Sanofi-Aventis U.S. LLC | $13.95 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.78 | 2024 | Xifaxan, Trulance |
| Vivus LLC | $13.25 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.